Ensysce completes PF614-MPAR trial enrollment

• Ensysce Biosciences completed enrollment in the final stage of its PF614-MPAR-102 clinical study.
• The trial evaluates MPAR technology designed to limit opioid release at excessive doses while maintaining therapeutic exposure.
• The program has Breakthrough Therapy designation and support from the National Institute on Drug Abuse.

Ensysce Biosciences (NASDAQ:ENSC) announced completion of enrollment in Part 3 of the PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology for opioid medicines.

The study is the second clinical evaluation of Ensysce’s Multi-Pill Abuse Resistance platform, which is designed to provide therapeutic opioid exposure at prescribed doses while limiting additional release at excessive doses.

Ensysce said published data from the program showed maintained therapeutic plasma levels at normal doses and reduced exposure at supratherapeutic dose levels, with PF614-MPAR supported by Breakthrough Therapy designation and National Institute on Drug Abuse funding.

The company said the completion of enrollment advances the PF614-MPAR program toward further evaluation, while following the announcement the Ensysce Biosciences share price was not provided.

Ensysce Biosciences develops drug delivery technologies focused on controlled-release medicines and abuse-resistant formulations for opioid and other therapeutic areas.

The company is also developing programs using its TAAP and MPAR platforms for pain, attention-deficit/hyperactivity disorder, opioid use disorder, and a psychedelic-based program for Complex Regional Pain Syndrome.